Voltar
Artigo Revisado por pares
BIBTEX RIS

Utilization study of filgrastim (Neutromax®) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients

2009; Elsevier BV; Volume: 41; Issue: 2 Linguagem: Inglês

10.1016/j.transci.2009.07.007

ISSN

1878-1683

Autores

Hugo H. Ferro, Mariana Juni, Ricardo J. Bello, Alejandro Vidal, Roberto A. Díez, S Pavlovsky,

Tópico(s)

Hematopoietic Stem Cell Transplantation

Resumo

To describe utilization of a biosimilar product containing filgrastim (Neutromax), data of 414 myeloma or lymphoma patients subjected to autologous SCT between 1998 and 2007 were analyzed. Filgrastim was used for mobilization of progenitors (5 days at 300 microg/day) and for the recovery of neutropenia after transplantation (100 microg/day, since day +5). In 2003, the excipient mannitol was replaced by sorbitol. A mean dose of 9.47 x 10(6)CD34(+)cells/kg was infused; 100 neutrophils/mm(3) required 5-day treatment; 500 neutrophils/mm(3), 6 days and 1000 neutrophils/mm(3), 7 days. Neutromax effect in SCT is similar to reports with other brands. No difference was found between formulations.

Referência(s)